FFF Enterprises: BioSupply Trends Newsletter
Monday, January 22, 2018

Repeated Influenza Vaccination
in Older Adults Reduces Severity
of Virus

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

New research has found repeated influenza vaccination in older adults is twice as effective in preventing severe influenza in those admitted to the hospital for the virus, compared with nonsevere cases, and that this effect is consistent regardless of flu season, virus subtypes or age of patient. [ read more ]

No Special Precautions Are Required for Influenza Vaccines in People with Egg Allergy

According to new practice parameters by the American College of Allergy, Asthma and Immunology (ACAAI), individuals with an egg allergy should receive their yearly flu shot, and no special precautions are required due to the tiny amount of egg protein contained in the vaccine. [ read more ]

Subcutaneous Prophylaxis with Bispecific Monoclonal Antibody Reduces Bleeding Rate in Hemophilia A and Inhibitors

Findings from a multinational Phase III study involving 109 male participants with hemophilia A and inhibitors showed that once-weekly subcutaneous prophylactic administration of an investigational bispecific humanized monoclonal antibody (emicizumab; ACE910) was associated with a significantly lower rate of bleeding events than no prophylaxis. [ read more ]

Industry News

 
 

From Dynavax Technologies Corp.

HEPLISAV-B, the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults, was approved by the U.S. Food and Drug Administration in November. [ read more ]

From GlaxoSmithKline

England’s National Institute for Health and Care Excellence has published draft guidance recommending GlaxoSmithKline’s Strimvelis as an option for treating adenoid deaminase deficiency-severe combined immunodeficiency when no suitable matched related stem cell donor is available.  [ read more ]

From Genentech

In December, the U.S. Food and Drug Administration approved Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence. [ read more ]

IVIG & Albumin Supply Index

 
 
 
 

NEW Issue of Biosupply Trends Quarterly!

Current Issue of BSTQ
 
 

In this Issue

•  The Misdiagnosis Dilemma
•  Growing Old with HIV
•  Expanding Uses of IVIG
•  Update on Diabetes
     
   
     

MyFluVaccine Loyalty Program

Want priority access on flu vaccines
for the 2019-2020 season?

Then take advantage of our NEW inclusive MFV Loyalty Program and enroll for the 2019-2020 season when you go to book your flu vaccine orders for the 2018-2019 season through MyFluVaccine.com

  • Priority access on advance released flu vaccines
  • No minimum purchase
  • Hassle-free
  • Guaranteed booking for the products you need

What's New at FFF

DAPTOMYCIN (TEVA)

DAPTOMYCIN (injection) is indicated for the treatment of adult and pediatric patients (1 to 17 years old) with complicated skin and skin structure infections caused by Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. Equisimilis and Enterococcus faecalis (vancomycin-susceptible isolates only). It is not indicated to treat pneumonia. It comes in 500 mg lyophilized powder for reconstitution in a single-dose vial.

For more information about DAPTOMYCIN, login to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Jan. 1, 2018, through Mar. 31, 2018.

 
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Carimune NF J1566 $68.83 $67.73
Flebogamma J1572 $67.31 $66.23
Gammagard S/D J1566 $68.83 $67.73
Gammaplex J1557 $77.62 $76.37
Octagam J1568 $71.18 $70.04
Privigen J1459 $76.96 $75.73
SCIG
CUVITRU J1555 $137.89 $135.68
Hizentra J1559 $98.31 $96.73
HyQvia J1575 $140.63 $138.37
IVIG / SCIG
Gammagard Liquid J1569 $81.45 $80.14
Gammaked J1561 $81.41 $80.10
Gamunex-C J1561 $81.41 $80.10

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2018 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.